Adverse Costs Insurance

Evaluate Adverse Costs Insurance against the underlying proceeding and exact policy or funding contract. Review liability theory, defenses, jurisdiction, procedural stage, counsel, evidence, damages, counterclaims, budget, adverse-cost exposure, appeal path, defendant solvency, settlement authority, insurance wording, exclusions, notice duties, limits, and consent requirements.

Construct probability-weighted outcomes for dismissal, trial loss, settlement ranges, judgment, appeal, delay, and enforcement. Then run each outcome through legal fees, case expenses, insurance premiums or recoveries, senior funding, return caps, taxes, and the contractual distribution waterfall. Claimed damages should never be inserted directly as expected proceeds.

Monitor pleadings, discovery, expert evidence, motions, budget burn, settlement posture, policy notifications, insurer reservations, security for costs, and defendant collectability. Warning signs include repeated budget extensions, missed notice deadlines, coverage disputes, changing damages theories, unfavorable interim rulings, or a recovery source whose financial condition is deteriorating.

Adverse Costs Insurance matters because specialty-asset investments usually depend on a narrow set of contractual rights, operational controls, and valuation assumptions rather than broad market liquidity. A public bond investor can often observe market price, trading volume, and issuer disclosures. A specialty-asset investor may have to rely on a PPM, an SPV agreement, a custody record, a royalty statement, a reserve report, a legal claim budget, an appraisal, or a sponsor-created model.

The central underwriting question is not only whether the asset is attractive. It is whether the investor has a financeable right to cash flow or collateral, whether that right is enforceable, who controls the asset or proceeds, and what happens if the expected timing slips. A strong deal memo should explain the cash source, the control point, the downside remedy, and the valuation method in plain operational terms.

Example: a collectibles loan, litigation finance exposure, drug royalty interest, insurance sidecar, and LP secondary can all advertise asset-backed or contractual cash flow. The actual risk is different in each case: authenticity and custody for collectibles, merits and defendant collectability for litigation, patent and reimbursement risk for royalties, event severity and collateral release for insurance, and unfunded commitments plus stale NAV for secondaries.

Legal right: identify exactly what is being purchased or financed. Is it a direct ownership interest, a note, a participation, a receivable, a royalty stream, an LP interest, a collateral assignment, a litigation proceeds interest, or a token representing an off-chain claim? Confirm whether the right is assignable, perfected, bankruptcy-remote, and senior or junior to other claims.

Control: determine who controls collections, custody, insurance, amendments, settlement decisions, sale timing, expense budgets, and reporting. A sponsor that controls both valuation and exit timing has more discretion than a structure with independent custody, third-party administration, investor consent rights, and hard distribution rules.

Valuation evidence: ask what supports the mark. Evidence can include closed transactions, administrator NAV, appraisals, auction comps, royalty statements, reserve reports, clinical sales data, legal damages analysis, insurance loss reports, or transfer-agent records. The weaker or older the evidence, the larger the valuation haircut investors should consider.

Downside path: map what happens if timing slips. If a lawsuit takes 5 years instead of 2, a drug royalty declines faster than forecast, a wine collection cannot be sold without a 25% discount, an insurance event traps collateral for multiple reporting periods, or an LP stake receives a capital call before an exit, the investor needs to know who funds the gap and whether distributions stop.

Common structures include single-asset SPVs, series LLC interests, participation agreements, revenue-share contracts, collateralized loans, royalty purchases, continuation vehicles, fund secondary transfers, insurance-linked notes, custody-backed financings, and tokenized wrappers. The wrapper determines what investors actually own and which remedies they have if the asset underperforms.

Payment priority should be explicit. A basic waterfall may pay operating expenses first, then senior lender principal and interest, then reserves, then preferred return, then residual upside. Small changes in priority can move economics materially. Example: a 2% annual servicing fee paid before investors on a delayed 5-year exit can consume far more value than the same fee on a 12-month asset sale.

Control over cash and records is often the real protection. Bank accounts, lockboxes, custodians, transfer agents, administrators, collateral agents, trustees, claims counsel, operators, and servicers can matter as much as the named asset. Investors should know whether proceeds bypass the sponsor or land first in a sponsor-controlled account.

Conflict review is essential. Specialty-asset sponsors may originate, value, service, warehouse, sell, and manage the same asset. Related-party fees, affiliated buyers, internal marks, rollover options, or sponsor discretion around settlements and exits should be disclosed and tied to investor consent rights where possible.

Useful metrics vary by asset class, but the reporting should connect contract value to realized cash. Litigation finance needs case status, budget burn, settlement posture, adverse-cost exposure, and defendant collectability. Collectibles need custody, insurance, condition, appraisal date, comparable sales, and liquidation channel. Royalties need gross receipts, deductions, payer statements, concentration, patent or contract duration, and audit rights. Secondaries need NAV date, discount, unfunded commitments, expected exits, and GP consent status.

Investors should compare base case, downside case, and delayed-exit case. Example: an asset underwritten to a 1.5x multiple over 3 years produces a different IRR if exit takes 5 years. A position marked at $1.0M with a target $1.5M sale may still be unattractive if custody, fees, taxes, appraisal slippage, and broker costs reduce net proceeds to $1.15M after a long hold.

Watch for stale valuations, missing counterparty data, unexplained markdown avoidance, related-party transactions, weak custody evidence, vague performance updates, repeated timeline extensions, or language that emphasizes activity instead of distributable cash. 'Progressing as expected' is not a substitute for proceeds, marks, reserves, and remaining risk.

Investor action: create a one-page bridge from legal right to cash. Start with the asset or contract, identify who owes money, identify who controls the payment channel, subtract senior claims and expenses, apply timing scenarios, then compare net proceeds with the investor's entry price. If that bridge cannot be built from available documents, the diligence file is incomplete.